Kala Bio Inc. has announced its financial results for the first quarter of 2025, ending March 31. The company reported a net loss of $8.9 million, a decrease from the $11.8 million net loss recorded in the same period of 2024. The operating loss for the quarter was $10.7 million, compared to $11.9 million in the first quarter of 2024. General and administrative expenses were $4.6 million, down from $5.4 million, primarily due to reduced employee-related costs. Research and development expenses were $6.1 million, slightly lower than the $6.4 million spent in the same period last year, largely due to decreased medical affairs-related costs for the development of KPI-012. On the business front, Kala Bio is progressing with its Phase 2b CHASE trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED), with topline data expected in the third quarter of 2025. The company aims for these results to potentially support a Biologics License Application $(BLA.AU)$ submission. As of March 31, 2025, Kala Bio's cash resources stood at $42.2 million, which are projected to fund operations into the first quarter of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.